In vivo administration of human recombinant granulocyte colony-stimulating factor (rG-CSF) was evaluated for effects on survival, hematologic recovery, and engraftment in an allogeneic murine bone marrow transplantation (BMT) model involving T-cell depletion. Post-BMT recipients of continuous subcutaneous infusions of rG-CSF) (n = 62) for 14 days had a significant survival advantage compared with post-BMT controls (n = 60) that received phosphate-buffered saline (PBS) infusions. Moreover, recipients of rG-CSF had significantly increased numbers of circulating leukocytes on days 7 and 14 post-BMT. Engraftment was not adversely affected. Administration of rG-CSF after transplantation of T-cell-depleted histoincompatible bone marrow benefits survival and leukocyte recovery without compromising engraftment.
|Original language||English (US)|
|Number of pages||6|
|State||Published - 1989|